#USA #Beijing #BeOne Medicines #Huahui Health #HH160

Huahui Health and BeOne Medicines Team Up for Cancer Breakthrough

On April 30, 2026, Huahui Health announced a groundbreaking global exclusive agreement with BeOne Medicines. This collaboration centers around HH160, a promising trispecific antibody aimed at revolutionizing cancer treatment through immunotherapy.

Under this agreement, BeOne Medicines has been granted the exclusive right to develop, manufacture, and commercialize HH160 worldwide. As part of the financial arrangements, BeOne Medicines will make an upfront payment of $20 million to Huahui Health. Once BeOne exercises the option, an additional $100 million will be paid, alongside potential milestone payments that could reach a staggering $1.9 billion depending on the achievements in development, regulatory approvals, and sales. Moreover, Huahui Health will benefit from tiered royalties on net sales of the drug.

The CEO of Huahui Health, Dr. Chen Bin, expressed enthusiasm regarding the partnership, highlighting the company’s comprehensive research and development capabilities. “Our pipeline, comprising a marketed product and several promising clinical programs, showcases the industry's recognition of our R&D skills. We are excited to collaborate with BeOne Medicines, leveraging their innovation and global expertise to bring HH160 to market,” Dr. Bin stated.

About HH160

HH160 is central to this collaboration. Utilized as a novel trispecific antibody, it was developed using Huahui Health's proprietary PolyBoost™ multispecific antibody platform. This drug is innovative in that it simultaneously targets three clinically validated targets in oncology: PD-1, CTLA-4, and VEGF-A. This unique “three-in-one” approach not only enhances therapeutic efficacy but also aims to ensure effective drug distribution to tumors while minimizing side effects.

Preclinical results showcasing the efficacy of HH160 were presented at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, reflecting strong early-stage results.

Huahui Health's Track Record

Founded in 2015 in Beijing, Huahui Health has been at the forefront of biopharmaceutical innovation, focusing on developing first-in-class therapies with a strong emphasis on oncology and viral hepatitis. Their commitment to addressing unmet needs is exemplified by the recent conditional approval from China’s NMPA for Libevitug, their first commercial product aimed at treating chronic hepatitis D infections. This product represents a significant advancement in hepatitis treatment, being recognized as China’s first approved therapy for HDV.

The Future of Innovation

Going forward, Huahui Health is determined to harness its innovation platforms and R&D strengths to continue developing groundbreaking therapies for cancer and liver diseases. With a robust pipeline advancing from preclinical studies to clinical trials, the company is well-positioned to deliver innovative solutions to patients globally. By integrating rigorous R&D processes with a patient-centric approach, Huahui Health aims to consistently produce and deliver effective drugs that improve patient outcomes. The partnership with BeOne Medicines is a significant step towards achieving these ambitious goals in cancer therapy.